Medicus Pharma Q3 2026 net loss per share narrows 79% to $11.64

• Medicus Pharma’s third-quarter 2026 net loss narrowed 5% year over year to $15.2 million.
• General and administrative expenses fell 50% to $2.5 million, while research and development spending rose 18% to $2 million year over year.
• CD228V became the principal development priority following a Pfizer licensing agreement, with an initial clinical proof-of-concept focus in melanoma.
• SkinJect entered a nonbinding agreement for a proposed SPAC combination contemplating an approximately $135 million pre-money enterprise valuation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611061630ACCESSWRNAPR_____1248599) on November 06, 2026, and is solely responsible for the information contained therein.